Medical Bulletin 28/April/2026

Here are the top medical news for today:

WHO Approves Infant Malaria Therapy, Introduces Additional Diagnostic Tests

A quiet breakthrough for the tiniest patients is reshaping the fight against malaria.

Just days after World Malaria Day on April 25, the World Health Organization announced a major milestone: the first-ever malaria treatment specifically designed for newborns and young infants weighing between two and five kilograms has been prequalified. This formulation of artemether-lumefantrine meets global standards for quality, safety, and efficacy—marking a critical step toward safer treatment for one of the most vulnerable groups.

Until now, infants with malaria were treated using drugs formulated for older children, raising risks of dosing errors and toxicity. The new infant-specific therapy is expected to improve care for millions, especially in countries like Africa, where nearly 30 million babies are born annually in malaria-endemic regions. Prequalification also enables wider public-sector procurement, helping bridge a long-standing treatment gap.

Alongside this, WHO had also prequalified three new rapid diagnostic tests (RDTs) to tackle a growing challenge: diagnostic failure. Traditional tests detect a malaria protein called HRP2, but in many regions, especially parts of the Horn of Africa, parasite strains have evolved to evade detection by deleting the gene responsible for this protein. In some areas, up to 80% of infections were being missed.

The newly approved tests target an alternative protein, pf-LDH, offering more reliable detection and ensuring timely treatment. WHO has recommended switching to these tests in regions where HRP2-based diagnostics fail in more than 5% of cases.

Despite significant progress—2.3 billion infections prevented and 14 million lives saved since 2000—malaria remains a global threat. According to the latest global report, 2024 saw 282 million cases and 610,000 deaths, highlighting stalled progress amid rising drug resistance and funding gaps.

Still, with new tools, vaccines, and innovations, the path toward ending malaria is becoming clearer—if momentum is sustained.

REFERENCE: WHO prequalifies first-ever malaria treatment for newborns and infants, adds new diagnostic tests; WHO; https://www.who.int/news/item/24-04-2026-who-prequalifies-first-ever-malaria-treatment-for-newborns-and-infants-adds-new-diagnostic-tests

Study Links Vitamin E Intake to Key Fertility Hormone in Women Trying to Conceive

Fertility may begin on the plate more than we realize.

A recent study published in Scientific Reports suggests that everyday nutrient intake could be linked to body composition and hormone levels in women experiencing infertility. As one in six couples worldwide face challenges conceiving, researchers are increasingly exploring how modifiable lifestyle factors—especially diet—might influence reproductive health.

The study examined 97 women aged 18–40 attending a fertility clinic in Spain, focusing on how their dietary patterns related to physical and hormonal markers. Participants typically had difficulty conceiving for at least a year, and conditions like polycystic ovary syndrome and endometriosis were excluded to avoid confounding effects.

Findings revealed a notable imbalance in body composition: most women had higher-than-recommended body fat percentages and slightly lower muscle mass, factors known to influence hormonal balance.

Higher intake of vitamin E was linked to lower prolactin levels—a hormone that, when elevated, can disrupt ovulation and menstrual cycles. Vitamin E intake was also associated with lower hip circumference, suggesting a potential role in fat distribution. Meanwhile, riboflavin (vitamin B2) and calcium intake were positively associated with muscle mass percentage, hinting at their broader role in metabolic and reproductive health.

While some nutrients initially appeared linked to hormones like anti-Müllerian hormone (AMH) and thyroid-stimulating hormone (TSH), these associations were not consistently significant. Importantly, the study does not prove cause and effect due to its cross-sectional design. Still, it highlights diet as a potentially important, modifiable factor in fertility care.

As research evolves, personalized nutrition could become a valuable addition to conventional fertility treatments—offering a practical way to support hormonal balance and overall reproductive health.

REFERENCE: Martín-Manchado, L., Sánchez-Sansegundo, M., Zaragoza-Martí, A., Serrado De La Cruz-Delgado, V., & Hurtado-Sánchez, J. A. (2026). Dietary nutrient intake and nutritional status in women with infertility: a cross-sectional study. Scientific Reports. DOI: 10.1038/s41598-026-47490-x https://www.nature.com/articles/s41598-026-47490-x

Scientists Uncover Connection Between Metabolic Processes, Immunity, and Skeletal Function

Fat inside bones is turning out to be far more dangerous than anyone expected.

A new study published in Bone Research challenges the long-held belief that higher body weight protects bone health. Instead, researchers show that obesity can actively weaken bones—not just through excess weight, but by reshaping the immune environment inside bone marrow.

At the center of this discovery is bone marrow adipose tissue, a specialized fat depot within bones. In obese mouse models, scientists observed a rapid expansion of this fat, which began releasing signaling molecules like MCP-1. This triggered an increase in immune cells expressing PD-L1, a key regulator in the PD-1/PD-L1 pathway. While this pathway is best known for suppressing immune responses, the study found it also plays a surprising role in bone breakdown.

These PD-L1-positive immune cells not only dampened T-cell activity—creating an immunosuppressive environment—but also directly promoted the formation of osteoclasts, the cells responsible for bone resorption. As osteoclast activity increased, bone density declined, affecting both trabecular and cortical bone structure.

Crucially, when researchers blocked the PD-1/PD-L1 interaction, osteoclast formation dropped significantly, suggesting a potential therapeutic target. Even more striking, genetically modified mice lacking bone marrow fat showed fewer immune disruptions and improved bone structure, despite being obese.

This research reframes bone marrow fat as an active driver of disease rather than a passive bystander. It also helps explain why obesity is linked not only to weaker bones but also to broader immune dysfunction, including poorer vaccine responses and higher infection risk.

The implications are far-reaching. Drugs targeting immune checkpoints—already used in cancer therapy—could one day be repurposed to treat obesity-related bone loss.

By uncovering this hidden link between metabolism, immunity, and skeletal health, the study opens the door to more integrated approaches in tackling chronic disease.

REFERENCE: Costa, S. N., et al. (2026). Expansion of bone marrow adipocytes in obese mice leads to PD-L1-driven bone marrow immunosuppression and osteoclastogenesis. Bone Research. DOI: 10.1038/s41413-026-00509-5. https://www.nature.com/articles/s41413-026-00509-5